Key Points
- Derek Maetzold sold 4,017 shares on Jan. 20 at an average price of $40.01 for a total of $160,720, reducing his stake by 4.38% to 87,715 shares (about $3.51M in value).
- Castle Biosciences has a market cap of roughly $1.23B, a one‑year price range of $14.59–$43.01, and recently reported quarterly revenue of $80.55M with EPS of ($0.02) that beat estimates.
- Institutional ownership is high (~92.6%), and analysts have an average rating of "Moderate Buy" with a consensus price target of $46, though individual ratings vary from sell to buy.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 4,017 shares of the firm's stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $40.01, for a total transaction of $160,720.17. Following the transaction, the insider directly owned 87,715 shares of the company's stock, valued at $3,509,477.15. The trade was a 4.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Castle Biosciences Stock Performance
NASDAQ CSTL opened at $42.15 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31. The stock has a market capitalization of $1.23 billion, a PE ratio of -93.67 and a beta of 1.06. Castle Biosciences, Inc. has a 1-year low of $14.59 and a 1-year high of $43.01. The business has a 50 day simple moving average of $39.03 and a two-hundred day simple moving average of $28.11.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.32. The company had revenue of $80.55 million for the quarter, compared to analysts' expectations of $71.06 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. On average, research analysts predict that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.
Institutional Investors Weigh In On Castle Biosciences
Hedge funds have recently made changes to their positions in the company. Amundi grew its position in shares of Castle Biosciences by 15,811.5% during the 1st quarter. Amundi now owns 4,137 shares of the company's stock worth $79,000 after buying an additional 4,111 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Castle Biosciences by 548.9% in the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company's stock worth $2,743,000 after acquiring an additional 115,907 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Castle Biosciences by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company's stock worth $309,000 after purchasing an additional 655 shares during the last quarter. Jones Financial Companies Lllp grew its stake in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company's stock valued at $54,000 after purchasing an additional 2,648 shares during the last quarter. Finally, Strs Ohio purchased a new stake in shares of Castle Biosciences during the first quarter valued at about $366,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on CSTL shares. Weiss Ratings reiterated a "sell (d)" rating on shares of Castle Biosciences in a report on Monday, December 29th. Guggenheim lifted their price objective on shares of Castle Biosciences from $30.00 to $43.00 and gave the stock a "buy" rating in a research note on Monday, January 5th. Zacks Research downgraded shares of Castle Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Friday, January 2nd. Robert W. Baird raised their target price on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an "outperform" rating in a report on Tuesday, November 4th. Finally, Canaccord Genuity Group upped their price target on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a "buy" rating in a report on Monday, December 22nd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Castle Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $46.00.
View Our Latest Report on Castle Biosciences
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
